Baltimore Checkbook: Gaithersburg-based MedImmune won't be impacted by AstraZeneca sale of antibiotic business to Pfizer

Thursday, August 25, 2016

Gaithersburg-based MedImmune won't be impacted by AstraZeneca sale of antibiotic business to Pfizer

Pharmaceutical giant AstraZeneca’s agreement to sell much of its antibiotics business won’t impact operations at MedImmune, its Gaithersburg-based research and development arm, officials confirmed Wednesday. MedImmune’s infectious disease and vaccine portfolio for AstraZeneca (NYSE: AZN) is focused exclusively on biologics, while AstraZeneca’s deal with Pfizer Inc. — worth up to $1.6 billion — is specific to its small molecule antibiotics business. Additionally, there is no production in AstraZeneca's…